NAPRA's 20th Anniversary / 20e anniversaire de l'ANORP
Pharmacy Technician Bridging Education Program-Course and PLAR exam schedules
Please note, this section will be updated periodically as the information becomes available.
Reminder: Courses and PLAR exams available in both English and French
NOTE: Selkirk College registration deadline for all English and French courses beginning in September 2015 is August 27, 2015
Rappel : Les cours et les examens ERA sont offerts en français et en anglais
REMARQUE : La date limite pour l’inscription aux cours (anglais et français) débutant en septembre 2015 au collège Selkirk est le 27 août 2015
Registration deadlines for all institutions are available on the Course and PLAR Schedules page.
Registration for all courses is conducted directly with the educational institution offering the program.
National Drug Schedules: Addition of mometasone nasal spray as a "drug not reviewed"
Mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older was removed from the Health Canada Prescription Drug List on August 12, 2015. In accordance with the NAPRA Policy for Drugs Not Reviewed, this drug was placed on Schedule I of the National Drug Schedules (NDS) and identified accordingly effective August 18, 2015. The status of this drug in the NDS can only change in the future if a submission is presented to NAPRA for a review by the National Drug Scheduling Advisory Committee (NDSAC).
Health Product Infowatch
The September issue of the Health Product InfoWatch published by Health Canada is now available. This monthly publication provides clinically relevant safety information on pharmaceuticals, biologics, medical devices and natural health products. Please consult the index for a complete listing of previous issues.
Health Product Risk Communication
Becton-Dickinson - Disposable Syringes and Reduced Drug Potency Issues
Certain lots of Becton-Dickinson (BD) general purpose disposable syringes with a specific type of stopper have been found to reduce the potency of some compounded or repackaged drugs stored in them. Compounded or repackaged drugs that have been stored in the affected lots of syringes should not be administered unless there is no suitable alternative available.
Health Canada Health Product Risk Communication
Health Canada proposes revised labelling standard for non-prescription acetaminophen products
Health Canada is seeking input on proposed revisions to strengthen the labelling standard for non-prescription acetaminophen products, to help consumers use these products more safely. As communicated in July 2015, this consultation is one of several steps Health Canada is taking to further minimize the risk of liver damage and improve acetaminophen safety.
Health Canada Information Update
Multiple sclerosis drug Gilenya (fingolimod): Safety information on the risk of skin cancer and a rare brain infection
Health Canada is informing Canadians that the drug label (product monograph) for the multiple sclerosis drug Gilenya (fingolimod) has been updated with new safety information on the risk of skin cancer, as well as a rare brain infection known as progressive multifocal leukoencephalopathy (PML).
Health Canada Information Update